Sequence: LLRLLRWWWRLLRLL
| Experiment Id | EXP002478 |
|---|---|
| Paper | In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Del |
| Peptide | WRAP5 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide:siRNA molar ratio R = 20; peptide concentration not separately reported. |
| Rna Concentration | 5, 10, 20, or 50 nM siRNA final concentration |
| Mixing Ratio | WRAP5:siRNA molar ratio R = 20; preincubated 30 min at room temperature in 5% glucose. |
| Formulation Format | peptide-based nanoparticle / non-covalent CPP:siRNA complex |
| Formulation Components | WRAP5:siRNA peptide-based nanoparticles formulated in 5% glucose; peptide:siRNA molar ratio R = 20; siFluc or siSCR; fluorescent siFluc-Alexa790/Cy3 included for imaging in some experiments. |
| Size Nm | 80.00 |
| Zeta Mv | 28.80 |
| Model Scope | in_vitro |
| Model Type | in vitro reporter-gene silencing |
| Cell Lines Or Primary Cells | U87-CMV/Fluc+Nluc+ and U87-CMV/Fluc-IRES-Nluc human glioblastoma reporter cell lines |
| Animal Model | |
| Administration Route | cell culture transfection; 1.5 h serum-free incubation followed by serum-containing medium |
| Output Type | in vitro functional reporter knockdown |
| Output Value | Dose-dependent Fluc silencing; Nluc unchanged when encoded on separate mRNA; both Fluc and Nluc decreased when encoded on common mRNA, supporting RNAi-mediated mRNA degradation. |
| Output Units | |
| Output Notes | This row captures in vitro functional siRNA delivery. It is not an in vivo delivery success even though the reporter knockdown was functional in cells. |
| Toxicity Notes | WRAP5:siSCR did not inhibit Fluc; authors report no toxicity of the PBN formulation in vitro. |
| Curation Notes |